Phase 1 Pancreatic Cancer Trial, Recruiting NCT04361708 Sponsor: University of Chicago Condition: Pancreatic Cancer
Back to Pancreatic Cancer

Phase 1 Pancreatic Cancer Trial, Recruiting

NCT04361708
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed (confirmed by a lab test) with a specific type of cancer in or near the digestive system, such as pancreatic cancer, stomach/esophagus cancer, bile duct cancer, gallbladder cancer, or a related type, that has spread locally or to other parts of the body
  • If you previously had yellowing of the skin or eyes caused by your tumor blocking a bile duct, that condition must now be mostly resolved and you must have a metal stent (a small tube) in place to keep the duct open
  • You are 18 years of age or older
  • You are reasonably active and able to care for yourself day-to-day (confirm with trial site)
  • Your doctor expects you to live for more than 3 months
  • Your blood counts, liver function, and kidney function are within acceptable ranges as measured by blood tests (confirm specific values with trial site)
  • Your cancer can be measured on scans, or may not need to be measurable at all
  • If you are a woman who could become pregnant, or a sexually active man, you must be willing to use effective birth control during treatment and for 3 months afterward
  • If you are a woman who could become pregnant, you must have a negative pregnancy test before starting the trial
  • If you are taking certain medications that interact with a drug called irinotecan, you should be willing to switch to alternatives where possible (confirm with trial site)

Who may not be able to join:

  • You have had radiation therapy for any cancer in the past
  • You have already had chemotherapy specifically for cancer that has spread to other parts of the body (though you may still be eligible if your cancer came back within 6 months of surgery-related chemotherapy — confirm with trial site)
  • You have an inflammatory bowel condition such as Crohn's disease or ulcerative colitis
  • You are currently experiencing diarrhea (note: pancreatic cancer patients with digestion problems must be taking enzyme replacement therapy to be considered)
  • You have moderate or severe nerve damage or nerve pain (such as numbness or tingling)
  • Cancer has spread to your brain
  • You have serious ongoing medical or mental health conditions that your doctor feels would make treatment too risky
  • You have active, uncontrolled bleeding
  • You are currently pregnant or breastfeeding
  • You have had major surgery within the past 4 weeks
  • You have had another type of cancer, unless it was an early-stage skin cancer or cervical cancer, or a previously treated cancer where the chance of it coming back is considered low (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Daniel Catenacci, MD, University of Chicago Medicine

Phone: 773-702-7596

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Registry
ClinicalTrials.gov
Start date
8 May 2020
Est. completion
1 June 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

The maximum dose tolerated

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov